Make NTRK gene fusion testing part of your patient care.
There are various methodologies to test for neurotrophic tropomyosin receptor kinase (NTRK) gene fusion, including immunohistochemistry (IHC), FISH, and RNA Fusion by next-generation sequencing (NGS).
Testing for NTRK gene fusions is essential to identify patients that harbor the genomic alterations who are now eligible for therapy that may ultimately address their cancer. It has been shown that patients with tumors driven by these gene rearrangements are excellent candidates for targeted tyrosine kinase receptor (TRK) inhibitors for locally advanced or metastatic solid tumors with NTRK fusions.
![NTRK cancer types](/sites/default/files/styles/lazy_load/public/2021-07/NTRK_Cancer_Types%20graphic.jpg?itok=5FglvATr)
NTRK gene fusion frequency1
NTRK gene fusions are a class of oncogenes associated with a wide range of pediatric and adult solid tumors.2 These genomic alterations may lead to TRK fusion proteins that are mutually exclusive oncogenic drivers that have been associated with more aggressive cancer in some tumor types.2-4
IHC | FISH | RNA Fusions by NGS |
---|---|---|
|
|
|
|
|
|
References:
- Hsiao, Susan J., et al. (2019) Jour Molec Diag.
- Stransky N, et al. Nat Commun. 2014;5:846.
- Park DY, et al. Oncotarget. 2015;7(7):8399-8412.
- Vaishnavi A, et al. Cancer Discov. 2015;5:25-34.
- Bourgeois JM et al. Am J Surg Pathol. 2000;24:937-946
- Murphy D. et al Appl lmmunohistochem Mol Morphol 2017:25:513-523.
- Kerr KM, Lopez-Rios F. Ann Oncol. 2016;27:iii16-iiii24.
- Cui C. et al. Front Cell Dev Biol. 2016;4:89
- Chae YK, et al Oncotarget. 2017;8:100863-100898.
- Church AJ, et al. Mod Pathol. 2018;31:463-473.